A single 79-year-old mystery patient got special access to Eli Lilly's experimental obesity drug retatrutide — and the White House won't say it wasn't President Trump. STAT broke the story Tuesday: a senior NIH clinician, Ranganath Muniyappa, requested the drug in April for a patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension. The request drew attention from top health officials — a telltale sign of connections. When STAT asked if...